| 2577 |
1262: Apoptosis |
1971: tumor growth |
Feb 15, 2022 |
Mar 5, 2024 |
1 AOP
|
| 2675 |
1262: Apoptosis |
2011: Emphysema |
Jun 17, 2022 |
Jun 17, 2022 |
1 AOP
|
| 2792 |
1262: Apoptosis |
2041: Decrease, outgrowth |
Oct 27, 2022 |
Apr 11, 2023 |
2 AOPs
|
| 2967 |
1262: Apoptosis |
352: N/A, Neurodegeneration |
Jul 18, 2023 |
Apr 11, 2024 |
1 AOP
|
| 3106 |
1262: Apoptosis |
2200: decline, neural progenitor cells |
Jan 10, 2024 |
Jan 10, 2024 |
1 AOP
|
| 2198 |
1817: Apoptotic cell death |
1633: Increase in inflammation |
Nov 2, 2020 |
Nov 2, 2020 |
1 AOP
|
| 2192 |
1814: Reactive Metabolite |
1816: Mitochondrial dysfunction EMPTY |
Nov 2, 2020 |
Nov 2, 2020 |
None
|
| 2194 |
1814: Reactive Metabolite |
1818: Immune cell activation |
Nov 2, 2020 |
Nov 2, 2020 |
1 AOP
|
| 3151 |
1814: Reactive Metabolite |
177: Mitochondrial dysfunction |
Mar 13, 2024 |
Mar 13, 2024 |
1 AOP
|
| 3199 |
1755: beta-catenin activation |
1457: EMT |
Apr 23, 2024 |
Apr 23, 2024 |
1 AOP
|
| 248 |
214: Bile accumulation, Pathological condition |
288: Activation of specific nuclear receptors, Transcriptional change |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 928 |
214: Bile accumulation, Pathological condition |
87: Release, Cytokine |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 930 |
214: Bile accumulation, Pathological condition |
249: Production, Reactive oxygen species |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 877 |
857: Binding as antagonist, Antagonist binding to PPARalpha ligand binding domain |
858: Decreased, PPARalpha transactivation of gene expression |
Nov 29, 2016 |
Nov 29, 2016 |
None
|
| 666 |
667: Binding at picrotoxin site, iGABAR chloride channel |
64: Reduction, Ionotropic GABA receptor chloride channel conductance |
Nov 29, 2016 |
Apr 29, 2019 |
1 AOP
|
| 3183 |
2218: Binding of (ant)agonist to liver X receptor |
2221: LXR activity, altered |
Apr 12, 2024 |
Apr 12, 2024 |
1 AOP
|
| 3187 |
2218: Binding of (ant)agonist to liver X receptor |
2115: Cholesterol metabolism |
Apr 12, 2024 |
Apr 12, 2024 |
1 AOP
|
| 3184 |
2219: Binding of (ant)agonist to PPAR alpha |
2216: Binding of antagonist to thyroid hormone receptor |
Apr 12, 2024 |
Apr 12, 2024 |
None
|
| 3185 |
2219: Binding of (ant)agonist to PPAR alpha |
2222: PPAR alpha activity, altered |
Apr 12, 2024 |
Apr 12, 2024 |
1 AOP
|
| 3188 |
2219: Binding of (ant)agonist to PPAR alpha |
2115: Cholesterol metabolism |
Apr 12, 2024 |
Apr 12, 2024 |
1 AOP
|
| 3195 |
2219: Binding of (ant)agonist to PPAR alpha |
2223: Reduced number of oligodendrocytes |
Apr 12, 2024 |
Apr 12, 2024 |
1 AOP
|
| 2304 |
1851: Binding of agonist, Angiotensin II receptor type 1 receptor (AT1R) |
257: Increase, ROS production |
Mar 30, 2021 |
Mar 30, 2021 |
None
|
| 2319 |
1851: Binding of agonist, Angiotensin II receptor type 1 receptor (AT1R) |
1115: Increased, Reactive oxygen species |
Apr 10, 2021 |
Apr 10, 2021 |
2 AOPs
|
| 919 |
875: Binding of agonist, Ionotropic glutamate receptors |
388: Overactivation, NMDARs |
Nov 29, 2016 |
Nov 29, 2016 |
2 AOPs
|
| 360 |
387: Binding of agonist, NMDARs |
388: Overactivation, NMDARs |
Nov 29, 2016 |
Nov 29, 2016 |
None
|